Pharmaceutical intermediates

Abemaciclib Intermediates

4 pharmaceutical intermediates for Abemaciclib. Indication: HR-positive, HER2-negative Breast Cancer / Node-positive Breast Cancer, Advanced Breast Cancer / Metastatic Breast Cancer.

提交项目 All intermediates

About Abemaciclib

Originator: Eli Lilly
Indication: HR-positive, HER2-negative Breast Cancer / Node-positive Breast Cancer, Advanced Breast Cancer / Metastatic Breast Cancer
Approved Date: 09/28/2017
DS/DP: 09/28/2031

Available intermediates

4 intermediates currently listed for Abemaciclib. Request specifications, documentation or a quotation for any item below.

Abemaciclib intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine	1180132-17-5	/	/
1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)-	1231930-42-9	/	/
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole	1231930-33-8	/	/
2,4-Dichloro-5-fluoropyrimidine	2927-71-1	/	/

Other programs under A

Abrocitinib Acalabrutinib Adagrasib Afatinib Afoxolaner Alectinib Hydrochloride Alfacalcidol Alogliptin/ Trelagliptin

Building toward Abemaciclib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →